CN103830226A - New medicinal application of silymarin - Google Patents
New medicinal application of silymarin Download PDFInfo
- Publication number
- CN103830226A CN103830226A CN201210490269.3A CN201210490269A CN103830226A CN 103830226 A CN103830226 A CN 103830226A CN 201210490269 A CN201210490269 A CN 201210490269A CN 103830226 A CN103830226 A CN 103830226A
- Authority
- CN
- China
- Prior art keywords
- silymarin
- endotoxin
- injection
- group
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to an application of silymarin in treating injury caused by bacterial infection, and particularly relates to an application in treating the endotoxemia and endotoxin shock resulting from the injury caused by bacterial infection.
Description
Summary
The present invention relates to the application of silymarin in damage due to preparation treatment antibacterial infects, the application in endotoxemia and endotoxin shock that due to treatment antibacterial infects, damage causes particularly.
Technical field
The present invention relates to silymarin and infect the application in endotoxemia and the endotoxin shock causing on treatment antibacterial.
Background technology
The clinical case fatality rate that antibacterial infects the endotoxemia that causes and shock thereof is very high, is a great problem in anti-infective therapy.Endotoxin (Endotoxin) is a kind of constituent of bacteria cell wall, its chemical nature is lipopolysaccharide (Lipopolysaccharide, LPS), when antibacterial infects, antibacterial or lipopolysaccharide (Lipopolysaccharide, LPS) are that endotoxin (Endotoxin) enters blood circulation, activate inflammation cell and discharge inflammatory mediator, the reaction that causes inflammation, can cause multiple organ dysfunction syndrome when serious.Therefore study effective anti-endotoxin medicine highly significant.
Silymarin is from Herba Silybi mariani, to extract the active component separating, and it has free radical resisting, stabilizing cell membrane and anti-liver injury effect bibliographical information.We study and find that silymarin can obviously reduce the dead mouse being caused by endotoxin; find that silymarin has obvious rising effect to the Blood pressure drop of the Shock in Rats being caused by endotoxin, the damage that endotoxemia causes has significant protective effect simultaneously.Based on this, the inventor provides silymarin to infect the application in the medicine of the endotoxemia that causes and shock on preparation treatment antibacterial.
Summary of the invention
The invention provides the application of silymarin in endotoxemia and endotoxin shock that due to treatment antibacterial infects, damage causes.
The invention provides taking silymarin as active component be used for the treatment of antibacterial infect due to the endotoxemia that causes of damage and the pharmaceutical composition of shock.This pharmaceutical composition can pass through oral, injection administration.Can there is with the form of tablet, pill, granule, capsule, suspension, solution, syrup, injection the preferred freeze-dried powder of injection preparation, injection vein emulsion.Various pharmaceutical dosage form provided by the present invention all can be prepared from pharmacy conventional method.
Silymarin of the present invention is when for above-mentioned arbitrary purposes, and its using dosage scope is 100-3000mg.
The inventor has confirmed the application of silymarin in the medicine of endotoxemia that due to treatment antibacterial infects, damage causes and shock by following test, but effect is not limited to this.
detailed description of the invention:
Preparation example 1: preparation injection silymarin freeze-dried powder
Take 100g silymarin, add water for injection 1000ml, adjusting pH is 8.5, adds 85 DEG C of insulations of 0.1% needle-use activated carbon 30 minutes, G
3sintered glass funnel filters, the filtering with microporous membrane of 0.22um; Filtrate is sub-packed in 10ml cillin bottle, and every loading amount 2ml, makes freeze-dried powder through freeze dryer lyophilizing.
Preparation example 2: preparation injection silymarin freeze-dried powder
Take 100g silymarin, add water for injection 1000ml, adjusting pH is 8.5, adds 85 DEG C of insulations of 0.1% needle-use activated carbon 30 minutes, G
3sintered glass funnel filters, the filtering with microporous membrane of 0.22um; Filtrate is sub-packed in 10ml cillin bottle, and every loading amount 2ml, makes freeze-dried powder through freeze dryer lyophilizing.
Preparation example 3: preparation injection silymarin Emulsion
| Silymarin | 100mg |
| Refined soybean oil | 10g |
| Refining soybean phospholipid | 2.0g |
| Poloxamer | 1.0g |
| Glycerol | 2.5g |
| Cholesterol | 0.5g |
| Water for injection | Add to 100ml |
Silymarin, fabaceous lecithin, cholesterol, with joining after dissolve with ethanol in refined soybean oil, are mixed to clear and brightly, and by rotary evaporation or pass into vaporized nitrogen and remove alcohol, obtain the soybean oil solution containing silibinin 10mg/ml and 50mg/ml cholesterol.
Poloxamer, glycerol are dispersed in water for injection, and under high-speed stirred condition, the phospholipid that slowly dropping contains silymarin, the oil solution of cholesterol, in dispersion, are made thick Emulsion.By obtained thick Emulsion under the condition of pressure 100Mpa, by the further emulsifying of dispersing emulsification machine, after emulsifying finishes in 115 DEG C, 30min sterilizing, subpackage and get final product.
Preparation example 6: prepare silymarin tablet
100g silymarin is crossed to 100 orders (lower same) sieve, add starch 100g to mix, sieve, obtain mixed powder, 75% ethanol water 120ml makes binding agent, make suitable soft material, 18 mesh sieves are granulated, 60 DEG C of oven dryings 2 hours, 16 order nylon mesh granulate, add magnesium stearate 8g, mix, oval special-shaped stamping is made 1000, the heavily about 200mg/ sheet of sheet.
the impact test that experimental example 1 silymarin is lethal on mice endotoxin
1 experiment material
Endotoxin: microorganism teaching and research room of Shanghai The 2nd Army Medical College;
Secondary Kunming kind white mice, body weight 19-21g.
Dexamethasone sodium phosphate injection (Pharmaceutical Lianshui, Tianjin company limited, specification: 5mg)
2 experimental techniques and result
Mice is divided into 8 groups at random: NS group, Dexamethasone group, intravenous injection silymarin 400mg/kg group, 100mg/kg group, 50mg/kg group, 20mg/kg group, 10mg/kg group, gastric infusion silymarin (600mg/kg) group, every group 20, male and female half and half, every mouse mainline endotoxin 20mg/kg, respectively organize immediately administration, NS group gives the NS of same volume, and mice occurs dead after 8 hours, stop to 48 hours dead mouses, respectively organize and between mortality rate group, carry out X
2inspection, carries out statistical procedures.
Table 1 result of the test show intravenous injection silymarin 20mg/kg, gastric infusion silymarin 600mg/kg can obviously reduce by endotoxin induced mice mortality rate (with NS group relatively,
p<0.05), intravenous injection silymarin 50mg/kg, 100mg/kg, 400mg/kg, can significantly reduce by endotoxin induced mice mortality rate (with NS group relatively,
p<0.01).
The impact (n=20) that table 1 silymarin is lethal on mice endotoxin
Compare with NS group,
△:
p<0.05;
△ △:
p<0.01.
Claims (2)
1. the application of silymarin in damage due to preparation treatment antibacterial infects.
2. the application of silymarin in endotoxemia and endotoxin shock that due to treatment antibacterial infects, damage causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210490269.3A CN103830226A (en) | 2012-11-27 | 2012-11-27 | New medicinal application of silymarin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210490269.3A CN103830226A (en) | 2012-11-27 | 2012-11-27 | New medicinal application of silymarin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103830226A true CN103830226A (en) | 2014-06-04 |
Family
ID=50794333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210490269.3A Pending CN103830226A (en) | 2012-11-27 | 2012-11-27 | New medicinal application of silymarin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103830226A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016065609A1 (en) * | 2014-10-31 | 2016-05-06 | Kimberly-Clark Worldwide, Inc. | Anti-adherent botanical compositions |
| US9969885B2 (en) | 2014-07-31 | 2018-05-15 | Kimberly-Clark Worldwide, Inc. | Anti-adherent composition |
| US10028899B2 (en) | 2014-07-31 | 2018-07-24 | Kimberly-Clark Worldwide, Inc. | Anti-adherent alcohol-based composition |
| US10238107B2 (en) | 2014-07-31 | 2019-03-26 | Kimberly-Clark Worldwide, Inc. | Anti-adherent composition |
| US11168287B2 (en) | 2016-05-26 | 2021-11-09 | Kimberly-Clark Worldwide, Inc. | Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface |
| US11737458B2 (en) | 2015-04-01 | 2023-08-29 | Kimberly-Clark Worldwide, Inc. | Fibrous substrate for capture of gram negative bacteria |
-
2012
- 2012-11-27 CN CN201210490269.3A patent/CN103830226A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9969885B2 (en) | 2014-07-31 | 2018-05-15 | Kimberly-Clark Worldwide, Inc. | Anti-adherent composition |
| US10028899B2 (en) | 2014-07-31 | 2018-07-24 | Kimberly-Clark Worldwide, Inc. | Anti-adherent alcohol-based composition |
| US10238107B2 (en) | 2014-07-31 | 2019-03-26 | Kimberly-Clark Worldwide, Inc. | Anti-adherent composition |
| US10292916B2 (en) | 2014-07-31 | 2019-05-21 | Kimberly-Clark Worldwide, Inc. | Anti-adherent alcohol-based composition |
| WO2016065609A1 (en) * | 2014-10-31 | 2016-05-06 | Kimberly-Clark Worldwide, Inc. | Anti-adherent botanical compositions |
| GB2547153A (en) * | 2014-10-31 | 2017-08-09 | Kimberly Clark Co | Anti-adherent botanical compositions |
| GB2547153B (en) * | 2014-10-31 | 2020-08-05 | Kimberly Clark Co | Anti-adherent botanical compositions |
| US11737458B2 (en) | 2015-04-01 | 2023-08-29 | Kimberly-Clark Worldwide, Inc. | Fibrous substrate for capture of gram negative bacteria |
| US11168287B2 (en) | 2016-05-26 | 2021-11-09 | Kimberly-Clark Worldwide, Inc. | Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103830226A (en) | New medicinal application of silymarin | |
| Xu et al. | Glycyrrhizin attenuates Salmonella enterica Serovar Typhimurium infection: new insights into its protective mechanism | |
| CN103127038A (en) | Novel application of patchouli alcohol | |
| Arsene et al. | Short review on the potential alternatives to antibiotics in the era of antibiotic resistance | |
| CN108685996B (en) | A topical natural medicinal composition for preventing and treating acne, and its preparation method | |
| RU2362577C2 (en) | Extract of common licorice, possessing antituberculous activity | |
| AU2018209227A1 (en) | Autologous fecal sample for use in the treatment of microbial dysbiosis | |
| CN111529671B (en) | New application of bupleurum tenue granules in combination with antibiotics | |
| CN109568301A (en) | A kind of gallic acid, Rhein compound prescription preparation method and applications | |
| Lin et al. | Nano-encapsulation of halofuginone hydrobromide enhances anticoccidial activity against Eimeria tenella in chickens | |
| CN113318149B (en) | Jasminum extract and preparation method and application thereof | |
| CN100546577C (en) | The new medical use of silibinin or its salt | |
| CN102068464A (en) | Antibacterial and antiviral effective part extract of medicated leaven and medicinal use thereof | |
| CN105918644A (en) | Feed additive for control of goldfish fin rot disease and preparation method thereof | |
| CN100546584C (en) | The pharmaceutical applications of icariin | |
| DE202008016879U1 (en) | antidiarrheal | |
| Lee et al. | Anti-proliferation effect of Hevea brasiliensis latex B-serum on human breast epithelial cells. | |
| CN114209732B (en) | Medicine for preventing and treating nocardiosis and application thereof | |
| CN1313499C (en) | Sargassum polysaccharide, its preparation method and use | |
| CN104523693A (en) | Antifungal compound preparation containing chlorogenic acid and application thereof | |
| Wang et al. | Chemical Composition and Antibacterial and Antiulcerative Colitis Activities of Essential Oil from Pruni Semen | |
| CN104523852B (en) | A kind of Chinese medicine composition of anti-flu and its application | |
| CN109394881A (en) | Prevent and treat pure Chinese medicine composition of poultry enterotoxin syndrome and preparation method thereof and application method | |
| Ovcinnikov et al. | Ultrastructure of gonococci in acute, chronic, and asymptomatic gonorrhoea. | |
| CN113813303B (en) | Application of cyclocarya paliurus leaf extract in preparation of antibacterial drug and/or antibacterial agent for inhibiting drug-resistant bacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140604 |